Provided by Tiger Trade Technology Pte. Ltd.

PHAXIAM THERAPEUTICS S A SPON ADR EACH REPR 1 ORD

3.10
0.0000
Volume:- -
Turnover:- -
Market Cap:18.83M
PE:-1.48
High:3.10
Open:3.10
Low:3.10
Close:3.10
52wk High:3.10
52wk Low:3.10
Shares:6.07M
Float Shares:4.51M
Volume Ratio:- -
T/O Rate:- -
Dividend:- -
Dividend Rate:- -
EPS(TTM):-2.0974
EPS(LYR):-0.0786
ROE:-38.62%
ROA:-15.05%
PB:0.44
PE(LYR):-39.46

Loading ...

Company Profile

Company Name:
PHAXIAM THERAPEUTICS S A SPON ADR EACH REPR 1 ORD
Exchange:
NASDAQ
Establishment Date:
- -
Employees:
- -
Office Location:
- -
Zip Code:
- -
Phone:
- -
Fax:
- -
Introduction:
PHAXIAM Therapeutics S.A., a biopharmaceutical company, focuses on developing treatments for resistant bacterial infections in France and the United States. It develops eryaspase, which is in Phase 3 clinical development for the treatment of second-line pancreatic cancer, and in Phase 2 stage for the treatment of triple-negative breast cancer and second-line acute lymphoblastic leukemia patients. The company also engages in developing a portfolio of phages targeting resistant and dangerous bacteria, which together account for more than two-thirds of resistant hospital-acquired infections, including staphylococcus aureus, escherichia coli, and pseudomonas aeruginosa. The company was formerly known as ERYTECH Pharma S.A. and changed its name to PHAXIAM Therapeutics S.A. in June 2023. PHAXIAM Therapeutics S.A. was incorporated in 2004 and is headquartered in Lyon, France.